Too early to discuss pricing of remdesivir: US Health Department

Gilead will be donating the first 1.5 mn doses to governments worldwide which according to Gilead will be enough for about 140,000 patients through the end of May

The Department of Health and Human Services has said that it is too early to discuss the pricing of 'remdesivir', the drug which has raised everyone's hopes of treating the coronavirus.

The department has however noted that US government has regularly reimbursed hospitals and other providers for treating people with no health insurance, the Washington Post reported.

So Gilead, the creator of the drug 'remdesivir' will be donating the first 1.5 million doses to governments worldwide which according to Gilead will be enough for about 140,000 patients through the end of May.

More than half of it has been targeted for the patients